Subscribe

Clinuvel Pharmaceuticals Limited (CUV.AX)

AUD9.98 -0.21 (-2.06%)
AU ASX Healthcare Biotechnology
Address 535 Bourke Street 3000
Melbourne, VIC, AU
CEO Philippe Jacques Wolgen
Website clinuvel.com
IPO 2001-02-11
ISIN AU000000CUV3

Explore sections of this company profile

Also trades on Australian Securities Exchange · CUV.AX (AUD) Other OTC · CLVLF (USD) Other OTC · CLVLY (USD)
Description

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
AUD9.98 -0.21 (-2.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
96.9K
Beta
0.61
Float Shares
41.57M
Free Float %
82.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.90% +0.55% +0.11% -8.79% -23.28% -26.73% -15.31% -50.78% -68.61% +90.21% +198.37%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
9.98
DCF (Unlevered) 27.46 +175.2%
DCF (Levered) 28.51 +185.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 7 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
16.34
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers ★ Strong MOAT
  • ✓
    Revenue growth Biotechnology: +1.6%
    +7.8% ★ Q4'25: +14.5% (vs Q4'23)
  • ✓
    EPS growth Biotechnology: +29.7%
    +2.9% Q4'25: +0.0% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Biotechnology: +16.2%
    +41.3% ★ Q4'25: +33.5% (vs Q4'23)
  • ✓
    EBIT margin Biotechnology: +0.0%
    +59.0% ★ Q4'25: +29.7% (vs Q4'23)
  • ✓
    ROIC Biotechnology: -16.1%
    +228.1% ★ Q4'25: +191.9% (vs Q4'23)
  • ✓
    Share dilution Biotechnology: -3.4%
    -1.3% ★ Q4'25: -1.9% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.01× ★ Q4'25: 0.01× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.61) × ERP
WACC = 100% × Ke + 0% × Kd (844.4%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 27.46 Current price: 9.98
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Jun 2015
actual 		Jun 2017
actual 		Jun 2018
actual 		Jun 2019
actual 		Jun 2020
actual 		Jun 2021
actual 		Jun 2022
actual 		Jun 2023
actual 		Jun 2024
actual 		Jun 2025
actual 		Jun 2026
7 Rev. Ana.
6 EPS Ana. 		Jun 2027
7 Rev. Ana.
6 EPS Ana. 		Jun 2028
7 Rev. Ana.
6 EPS Ana. 		Jun 2029
3 Rev. Ana.
3 EPS Ana.
Revenue
3.32M
est: 21.00M (-84.2%)
16.77M
est: 21.00M (-20.2%)
25.49M
est: 46.30M (-45.0%)
31.05M
est: 31.00M (+0.2%)
32.57M
est: 34.00M (-4.2%)
47.98M
est: 43.63M (+10.0%)
65.72M
est: 63.70M (+3.2%)
78.32M
est: 79.55M (-1.5%)
88.18M
est: 87.08M (+1.3%)
95.02M
est: 99.01M (-4.0%)
99.22M
95.82M – 104.50M
+0.2% YoY
105.71M
101.14M – 111.78M
+6.5% YoY
162.11M
155.81M – 171.09M
+53.4% YoY
427.81M
411.20M – 451.51M
+163.9% YoY
EBITDA
-10.79M
est: 12.41M (-187.0%)
6.85M
est: 12.41M (-44.8%)
12.26M
est: 27.35M (-55.2%)
18.35M
est: 18.31M (+0.2%)
11.99M
est: 20.08M (-40.3%)
28.19M
est: 25.77M (+9.4%)
35.08M
est: 37.63M (-6.8%)
46.37M
est: 46.99M (-1.3%)
56.28M
est: 57.61M (-2.3%)
57.20M
est: 65.50M (-12.7%)
65.64M
63.39M – 69.13M
+0.2% YoY
69.93M
66.91M – 73.95M
+6.5% YoY
107.24M
103.08M – 113.18M
+53.4% YoY
283.02M
272.03M – 298.69M
+163.9% YoY
EBIT
-11.26M
est: 12.13M (-192.8%)
6.70M
est: 12.13M (-44.8%)
12.15M
est: 26.75M (-54.6%)
18.14M
est: 17.91M (+1.3%)
11.54M
est: 19.64M (-41.2%)
27.33M
est: 25.21M (+8.4%)
36.60M
est: 36.80M (-0.6%)
48.77M
est: 45.96M (+6.1%)
55.13M
est: 56.88M (-3.1%)
56.02M
est: 64.68M (-13.4%)
64.81M
62.60M – 68.26M
+0.2% YoY
69.05M
66.07M – 73.02M
+6.5% YoY
105.89M
101.78M – 111.76M
+53.4% YoY
279.46M
268.61M – 294.94M
+163.9% YoY
Net Income
-10.40M
est: 307.3K (-3,483.5%)
7.18M
est: 307.3K (+2,236.6%)
13.22M
est: 24.18M (-45.3%)
18.13M
est: 17.63M (+2.8%)
16.65M
est: 13.10M (+27.1%)
24.73M
est: 19.03M (+30.0%)
20.88M
est: 20.48M (+1.9%)
30.60M
est: 30.60M (+0.0%)
35.64M
est: 32.96M (+8.1%)
36.17M
est: 39.42M (-8.2%)
35.94M
30.03M – 41.68M
-8.8% YoY
38.20M
34.34M – 45.19M
+6.3% YoY
49.87M
33.10M – 88.70M
+30.6% YoY
226.51M
215.08M – 242.82M
+354.2% YoY
SGA
11.31M
est: 4.31M (+162.2%)
5.69M
est: 4.31M (+32.0%)
6.34M
est: 9.51M (-33.4%)
6.29M
est: 6.37M (-1.3%)
12.23M
est: 6.98M (+75.1%)
7.96M
est: 8.96M (-11.2%)
12.30M
est: 13.08M (-6.0%)
8.41M
est: 16.34M (-48.5%)
25.03M
est: 17.89M (+39.9%)
26.85M
est: 20.34M (+32.1%)
20.38M
19.68M – 21.46M
+0.2% YoY
21.71M
20.77M – 22.96M
+6.5% YoY
33.29M
32.00M – 35.14M
+53.4% YoY
87.87M
84.46M – 92.73M
+163.9% YoY
EPS
-0.24
est: 0.01 (-4,034.4%)
0.15
est: 0.01 (+2,359.0%)
0.28
est: 0.48 (-41.7%)
0.38
est: 0.35 (+8.6%)
0.31
est: 0.26 (+19.2%)
0.50
est: 0.38 (+32.4%)
0.42
est: 0.41 (+3.3%)
0.62
est: 0.61 (+1.6%)
0.72
est: 0.66 (+9.2%)
0.72
est: 0.79 (-8.3%)
0.72
0.60 – 0.83
-7.9% YoY
0.77
0.68 – 0.90
+7.0% YoY
1.00
0.66 – 1.76
+29.1% YoY
4.50
4.27 – 4.82
+349.9% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-28 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-27 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-26 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-25 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-22 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-21 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-20 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-19 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-18 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-15 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-14 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-13 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-12 A 4/5 5/5 4/5 5/5 4/5 2/5 3/5
2026-05-11 A+ 4/5 5/5 4/5 5/5 4/5 3/5 3/5
2026-05-08 A+ 4/5 5/5 4/5 5/5 4/5 3/5 3/5
2026-05-07 A+ 4/5 5/5 4/5 5/5 4/5 3/5 3/5
2026-05-06 A+ 4/5 5/5 4/5 5/5 4/5 3/5 3/5
2026-05-05 A+ 4/5 5/5 4/5 5/5 4/5 3/5 3/5
2026-05-04 A+ 4/5 5/5 4/5 5/5 4/5 3/5 3/5
2026-05-01 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-30 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-29 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-28 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-27 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-24 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-23 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-22 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-04-21 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-20 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-17 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-16 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
65.58M
OE per share TTM
1.30
Owner's Yield
14.32%
Maintenance CapEx ratio
1.23%
Maint CapEx / Avg PPE
5.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 33 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares S&P/ASX Small Ordinaries ETF ISO.AX 0.16% 139.4K 0.55%
2 iShares International Small-Cap Equity Factor ETF ISCF 0.02% 132.7K 0.24%
3 State Street SPDR S&P International Small Cap ETF GWX 0.02% 167.6K 0.40%
4 Vanguard Australian Shares Index ETF VAS.AX 0.01% 2.55M 0.07%
5 Avantis International Small Cap Equity ETF AVDS 0.01% 39.5K 0.30%
6 Schwab International Small-Cap Equity ETF SCHC 0.01% 634.7K 0.06%
7 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.01% 1.00M 0.06%
8 Dimensional - International Small Cap ETF DFIS 0.01% 390.0K 0.39%
9 Vanguard FTSE Pacific ETF VPL 0.00% 338.1K 0.07%
10 Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO 0.00% 5.4K 0.22%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
3.50M
Shares Outstanding
50.41M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Philippe Jacques Wolgen Chief Executive Officer, MD & Director 5M —
Lachlan Hay Chief Operations Officer 550.0K male
Dennis J. Wright Chief Scientific Officer 367.7K —
Peter Vaughan Chief Financial Officer 337.7K male
Azza Hamila Head of Quality Assurance & Drug Safety — —
Malcolm Bull Head of Australian Operations & Investor Relations — male
Claire Newstead-Sinclair Company Secretary — female
Linda Teng Director of North American Operations — —
Emilie Rodenburger Director of Global Clinical Affairs — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology